One Long Island Cancer Network's Doctors and PAC Have Given Him $55,137. The Last Check Came 15 Days Before His Biosimilars Bill.

Campaign Finance / Healthcare Source: FEC bulk files, govinfo BILLSTATUS, Senate LDA, Politico DOCUMENTED PATTERN

Original source →

Why this matters

None of this network’s cancer centers is in his district. Its doctors are among his campaign’s most coordinated donor blocs anyway, and this year he became a sponsor of legislation that the economics of their industry favor.

Say the fair part first, because here it is unusually strong: the bill is bipartisan, it codifies a policy the FDA itself announced nine months earlier, a Democratic physician is its co-lead, and its endorsers include insurers, employers, pharmacists and a Buffalo cancer center that actually treats his constituents. Nothing in this entry says the bill is bad policy, and nothing in it alleges a deal. What it documents is the money, the dates, and the fact that none of the disclosures mention each other.

The money

New York Cancer & Blood Specialists (NYCBS) is a community oncology network headquartered in Port Jefferson Station, Long Island, led by CEO Dr. Jeff Vacirca. Its locations are in Suffolk, Nassau, the five boroughs, Westchester, Dutchess and Orange counties. None is in NY-23.

From FEC records, memo entries and refunds excluded:

SourceAmountDetail
56 contributions from NYCBS-employed donors$40,13738 list “physician,” 11 “MD,” 4 “CEO”
Conquering Cancer PAC (C00785014, run by NYCBS leadership)$15,000$5,000 each on Sep 18 2024, Feb 28 2025, Jun 29 2026
Total NYCBS-linked$55,137

All but $250 of the individual money arrived in three tight waves, the signature of organized bundling rather than 56 coincidences:

WaveAmount
July 26, 2024$10,305
February 25–26, 2025$22,582
May 6–11, 2026$7,000 (both gifts from Dr. Vacirca)
(single gift, Aug 5, 2024)$250

Dr. Vacirca personally accounts for $9,041 of the individual total. He is a past president of the Community Oncology Alliance (2017–2018) and a co-founder of OneOncology. NYCBS’s chair of legislative affairs, Dr. David Eagle, another COA past president who has testified before Congress, also appears in the donor list.

This is not a Langworthy-specific operation, and that matters. NYCBS-employed donors have given roughly $2.4 million federally across the last four cycles, concentrated on health policymakers of both parties: six-figure sums toward Cathy McMorris Rodgers and Rep. LaLota, large amounts to Reps. Comer, Bucshon, Guthrie and Miller-Meeks and Sens. Cassidy and Barrasso, and money to Democrats including Rep. Suozzi. Politico documented the operation in October 2024 under the headline “A New York medical group fills politicians’ coffers,” reporting that the network’s giving vehicle, Conquering Cancer PAC, had given to Langworthy among many others, and quoting Vacirca that he backs candidates who fight insurers and pharmacy benefit managers. Langworthy’s $55,137 makes him a mid-tier recipient in that program, not its centerpiece.

The bill

On July 14, 2026, Langworthy introduced H.R. 9661, the Expedited Access to Biosimilars Act, with Rep. Kim Schrier (D-WA), a physician, as original cosponsor. It amends the Public Health Service Act so that comparative efficacy studies are not automatically required to license a biosimilar, while preserving FDA’s authority to require them case by case.

Fifteen days earlier, on June 29, Conquering Cancer PAC had made its third $5,000 contribution. Two months earlier, in May, Dr. Vacirca had made his two largest personal contributions to Langworthy, $3,500 each.

Why the subject matters to community oncology: practices buy physician-administered drugs and are reimbursed at the average sales price plus a markup, with biosimilars deliberately paid at the biosimilar’s price plus a percentage of the more expensive reference product’s price. More approved biosimilars means lower acquisition costs against that markup. Biologics are 5 percent of prescriptions and 51 percent of drug spending, per FDA. The Community Oncology Alliance has formally supported biosimilar adoption since 2019.

His July 15 press release announcing the bill names its policy endorsers: Roswell Park, AHIP, the Association for Accessible Medicines, employers, pharmacists, Americans for Prosperity. It does not mention the oncology network whose doctors and PAC are among his largest out-of-district donors. That is not a disclosure the law requires. It is the same gap this site documented in the Seneca Nation entry and the American Chemistry Council entry, which is what makes it a pattern.

The fair reading, at full strength

This entry would be misleading if it left the impression that the bill is a favor. The documented record cuts hard the other way:

  • The FDA got there first. On October 29, 2025, the FDA announced draft guidance to stop routinely requiring comparative efficacy studies, citing their roughly $24 million cost and one-to-three-year duration per study, with the HHS Secretary and FDA Commissioner framing it as a drug-pricing action. The bill codifies that direction; it did not invent it.
  • The idea predates his involvement. Sen. Rand Paul introduced the identically titled S. 1414 in April 2025, fifteen months before Langworthy’s bill. It was reported out of the Senate HELP Committee in July 2026 with bipartisan cosponsors. A second Senate companion, S. 5059, is also bipartisan.
  • The support is broad, not sectoral. Insurers, large employers, hospital group purchasers, pharmacists, the generic-drug industry and a payer-funded pricing coalition endorsed it, along with Roswell Park, the Buffalo cancer center that actually serves Western New York. No organized patient-group or brand-pharma opposition to this bill was found, and that is a finding, not a gap.
  • No lobbying tie appears in the disclosures. NYCBS is not a registered lobbying client, and the Community Oncology Alliance’s filings through mid-2026 name PBM, 340B and Medicare reimbursement issues, not biosimilar licensure or this bill. Third-quarter filings, covering the month the bill moved, are not due until October.

A member sponsoring a bipartisan, FDA-endorsed cost-cutting bill that his donors’ industry also happens to like is what interest-aligned politics looks like when it is working legally and in the open. The reason it belongs on this site anyway is the same reason the ACC entry does: constituents reading the press release get the policy case, and only the FEC database gets the donors.

Questions this raises

  1. Has the Congressman or his staff met with NYCBS, Conquering Cancer PAC, or the Community Oncology Alliance about biosimilars policy, and when?
  2. His press release quotes seven endorsing organizations. Was the bill discussed with any of the donors documented here before introduction?
  3. The network’s giving is concentrated on members with health-policy jurisdiction, and he joined the Energy and Commerce Health Subcommittee in December 2024. His first NYCBS bundle arrived seven months later. Does his office see a connection between committee assignment and this donor base?
  4. Will he disclose fundraising events associated with the July 2024, February 2025 and May 2026 contribution waves?

Sources

Money (primary, computed from bulk files; extracts in research/sources)

  • FEC itcont bulk files, 2024 and 2026 cycles, streamed August 28, 2026; NYCBS extract: research/sources/nycbs-contributions-langworthy-2024-2026.txt
  • FEC itpas2 bulk files (Conquering Cancer PAC C00785014 to C00817932: 9/18/2024, 2/28/2025, 6/29/2026, $5,000 each)
  • Conquering Cancer PAC, FEC committee page: https://www.fec.gov/data/committee/C00785014/
  • FEC DuckDB index (NYCBS-employer giving across all recipients, ~$2.4M, cycles 2020–2026)

The bill

The network and the pattern

Note: This entry documents publicly available information. It does not allege any agreement, exchange, or unlawful conduct by anyone, and the contributions described are lawful and publicly disclosed. Neither Rep. Langworthy’s office, NYCBS, nor the Community Oncology Alliance has been asked for comment as of this writing; see the hold note.

Last updated: August 28, 2026